Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq: HROW) reported record Q4 revenue of $89.1M (up 33% YoY) and full-year 2025 revenue of $272.3M (up 36% YoY). GAAP net income was $6.6M in Q4 while full-year GAAP showed a $5.1M net loss. Adjusted EBITDA was $24.2M in Q4 and $61.9M for 2025. Harrow generated $43.9M operating cash flow in 2025 and ended the year with $72.9M cash. 2026 guidance: revenue $350M–$365M and Adjusted EBITDA $80M–$100M.
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.
Harrow (Nasdaq: HROW) launched PharmaPack, a Direct-to-Prescriber cash-pay program on Feb 17, 2026, offering FDA-approved ophthalmic kits as affordable alternatives to compounded products.
Initial availability covers California, Mississippi, Arkansas, Connecticut, and Alabama, with nationwide expansion planned in the coming weeks.
OSRX (HROW) confirmed it remains fully licensed, FDA-registered and operational in California and all 50 states following a competitor's market exit.
According to the company, ImprimisRx voluntarily forfeited its California license on Feb 1, 2026 and agreed to pay an administrative fine of approximately $157,000 to the California Board of Pharmacy. OSRX says it supports thousands of ophthalmologists and optometrists and offers direct-to-patient and direct-to-facility dispensing of compounded ophthalmic medications.
Harrow (Nasdaq: HROW) reaffirmed full-year 2025 revenue guidance of $270–$280 million and announced operational expansions: doubling the VEVYE sales force by Memorial Day 2026, doubling the surgical sales force for TRIESENCE, and expanding IHEEZO into office-based procedures (estimated >2.5 million annual use cases).
The company is on track to file NDAs for MELT-300 and MELT-210 in H1 2027, launched the OneHarrow branding initiative, promoted Patrick W. Sullivan to Chief Commercial Officer, and ImprimisRx settled California regulatory matters with a ~$157,000 fine and exited California effective Feb 1, 2026.
Harrow (Nasdaq: HROW) announced management will present at two investor conferences in December 2025.
Events and formats:
- BTIG 5th Annual Ophthalmology Day (virtual) — fireside chat on Monday, December 1, 2025 at 8:30 AM ET.
- Piper Sandler 37th Annual Healthcare Conference (New York, NY) — fireside chat on Tuesday, December 2, 2025 at 3:00 PM ET. The Piper Sandler talk will be webcast live on the company website and a replay will be available for approximately 90 days.
Harrow (Nasdaq: HROW) closed the acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400 based on a Zydis oral-dissolving tablet platform.
MELT-300 is a sublingual fixed-dose midazolam (3mg) + ketamine (50mg) formulation that completed Phase 2 and Phase 3 programs with stated statistical superiority to midazolam alone. Harrow plans one non-clinical and three PK studies to complete an NDA filing in H1 2027, regulatory review targeting H1 2028, and commercial launch in H2 2028. Harrow cites >800 U.S. ophthalmic institutions using its MKO Melt compounded product as a commercial foothold.
Harrow (Nasdaq: HROW) reported Q3 2025 total revenues of $71.6 million, a 45% increase versus $49.3 million in Q3 2024, and adjusted EBITDA of $22.7 million. GAAP net income for the quarter was $1.0 million and cash and cash equivalents were $74.3 million as of September 30, 2025.
Operational highlights include new national payer coverage agreements for VEVYE effective January 1, 2026, expansion of the VEVYE Access For All program via a partnership with Alto Pharmacy Powered by Fuze Health, the launch of Harrow Access for All (HAFA), and an agreement to acquire Melt Pharmaceuticals, maker of MELT-300.
Harrow (Nasdaq: HROW) will report third quarter 2025 financial results for the period ended September 30, 2025, on Monday, November 10, 2025 after market close. The company said it will post a Third Quarter Letter to Stockholders on its Investors page at harrow.com.
Harrow will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 11, 2025 to discuss results and provide a business update. A replay will be available on the company website for one year. Telephone participants must register in advance to receive a unique dial-in and PIN.
Harrow (Nasdaq: HROW) announced leadership changes at its ImprimisRx subsidiary on October 6, 2025. Frank Mullery was appointed Chief Executive Officer; he has >20 years in healthcare, led Sintetica US commercialization, served as President of Mylan Institutional where revenues exceeded $1 billion in 2018, and held senior finance roles. Bridseida Cruz was appointed Head of Quality; she has >25 years in quality and operations, led FDA remediation efforts, commissioned a new FDA-registered compounding facility, and delivered a 20% improvement in operational throughput while achieving zero critical FDA observations on inspection.
The board frames the hires as supporting Harrow’s vision to expand ImprimisRx’s ophthalmic compounding leadership and operational phase.